Pre-made Vudalimab benchmark antibody ( Bispecific Mixed mAb and scFv, anti-CTLA4/CTLA-4;PDCD1/PD-1 therapeutic antibody, Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3;CD279/SLEB2/hPD-1/hPD-l/hSLE1 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Vudalimab biosimilar, Bispecific Mixed mAb and scFv, Anti-CTLA4/CTLA-4;PDCD1/PD-1 Antibody: Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3;CD279/SLEB2/hPD-1/hPD-l/hSLE1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Vudalimab (formerly XmAb 20717 or XmAb 717) is a bispecific antibody being developed by Xencor, for the treatment of solid tumours. Xencor is using its Xtend Fc domain technology (a part of Xencor's proprietary XmAb® technology) that increases binding affinity to the receptor FcRn.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-631-1mg	1mg	Inquiry
GMP-Bios-ab-631-10mg	10mg	Inquiry
GMP-Bios-ab-631-100mg	100mg	Inquiry
GMP-Bios-ab-631-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Vudalimab biosimilar, Bispecific Mixed mAb and scFv, Anti-CTLA4/CTLA-4;PDCD1/PD-1 Antibody: Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3;CD279/SLEB2/hPD-1/hPD-l/hSLE1 therapeutic antibody
INN Name	Vudalimab
Target	CTLA-4;PD-1
Format	Bispecific Mixed mAb and scFv
Derivation	Bispecific antibody
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa;Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None;None
99% SI Structure	None;None
95-98% SI Structure	5tru:HL/5xj3:DE/6jc2:HL/6rp8:hl;None
Year Proposed	2020
Year Recommended	2021
Companies	Xencor
Conditions Approved	na
Conditions Active	Solid tumours
Conditions Discontinued	na
Development Tech	na